---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-22-000025"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:48:25.919743+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin reports record Q2 revenues of $534M; raises FY2022 guidance on Voxzogo growth

## Summary
- Total revenues $533.8M (+6% YoY); GAAP net income $27.7M vs $12.9M in Q2 2021.
- Voxzogo contributed $34.4M (first full quarter of U.S./EU sales); 446 children treated globally as of June 30.
- FY2022 total revenue guidance raised to $2.06-2.16B; Voxzogo net product revenue guidance raised to $130-160M.
- Expects EC approval of Roctavian for hemophilia A in Q3; BLA resubmission in U.S. planned for September 2022.
- Kuvan revenues declined 27% YoY to $57.6M due to generic competition; total revenues growth excluding Kuvan was 13% YoY.

## SEC filing metadata
- accession: 0001048477-22-000025
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000025/0001048477-22-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000025/bmrn-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-22-000025
- JSON: https://secwatch.observer/filing/0001048477-22-000025.json
- Plain text: https://secwatch.observer/filing/0001048477-22-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.